Real-World Experience with ¹⁷⁷ Lu-PSMA-617 Radioligand Therapy After Food and Drug Administration Approval.

Autor: Moradi Tuchayi A; Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California., Yadav S; Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California., Jiang F; Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California; and., Kim ST; Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California., Saelee RK; Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California., Morley A; Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California., Juarez R; Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California., Lawhn-Heath C; Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California., Wang Y; Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California., de Kouchkovsky I; Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, California., Hope TA; Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California; thomas.hope@ucsf.edu.

Publikováno v: Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2024 May 01; Vol. 65 (5), pp. 735-739. Date of Electronic Publication: 2024 May 01.